Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

In a functioning system, the kind of placebo-controlled vaccine trials that Secretary Kennedy is calling for would never get past an IRB, much less progress to an IND application. Vaccines are being ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

The Acuvue Oasys Max 1-Day Multifocal marks the first and only daily disposable contact lens to be available for people with ...

Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...